A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples